Rallis India Limited

The Indian agrochemical sector is transitioning from a buyer's to a seller's market due to war-induced supply constraints and rising prices, with Glyphosate prices up approximately 25%. The Q4 period was slow for domestic agrochemicals, and the Rabi season was impacted by unfavorable climate, damaging crops across 2.49 lakh hectares. The IMD's 2026 monsoon forecast of 92% of Longest Period Average (LPA) signals below-normal rains, potentially risking 5-10% demand cuts for herbicides/insecticides. Integrated firms with balanced portfolios (seeds + crop protection) are expected to fare best amid this volatility.

Rallis India reported a 6.04% YoY revenue growth in Q4 FY26, reaching ₹456 crores, compared to ₹430 crores in Q4 FY25. EBITDA improved significantly by 94.7% YoY to -₹1 crore (from -₹19 crores), and PAT improved 53.13% YoY to -₹15 crores (from -₹32 crores). For the full financial year FY26, topline revenue grew 9% YoY to ₹2897 crores. This growth was supported by an 8% increase in Crop Care revenue to ₹2416 crores and a 15% increase in Seeds revenue to ₹481 crores.

In Q4 FY26, the Domestic (B2C) business grew 15% to ₹255 crores, driven by a 14% volume increase, primarily in insecticides. The Soil & Plant Health category saw a 27% revenue growth to ₹47 crores, with a robust 29% volume growth, mainly from micronutrients and biofertilizers. The Seeds business grew 23% to ₹31 crores, benefiting from 8% volume and 15% price growth, particularly in cotton and millets. However, Exports topline de-grew 33% to ₹77 crores, while CSM revenue showed strong growth of 59% to ₹66 crores.

The company is facing a significant increase in raw material costs, ranging from 15% to 25%, driven by global supply chain disruption^🌐s and geopolitical tensions. Management stated that they have tried to pass on all cost increases and have announced price increases. They expect new prices to establish as carryover low-priced inventory from Q4 clears, indicating potential for higher realizations and margin protection in the coming quarters^⏳. This strategy is crucial to mitigate the impact of the cost inflation wave.

Management confirmed that industry-wide inventory levels have normalized, moving past the 'inventory hangover' experienced two years ago. Rallis is adopting a conservative approach to inventory, specifically stating they are not building inventory beyond Kharif. This disciplined strategy aims to mitigate risks associated with potential price drops if geopolitical tensions ease and to ensure calibrated buying and selling, avoiding excess stock.

Rallis launched new products such as ALSTOR, a dual-action granular insecticide, and FIPLAM, a broad-spectrum formulation. They also secured registration for Spiro, a three-way patented herbicide for Paddy, and introduced two new seed products. The company is enhancing its digital capabilities with the Idea2Impact platform for open innovation and Saksham (GIS platform) for targeted market expansion, aiming for high-margin, sustainable, and farmer-centric offerings.

The aquafeed business is currently in an experimental stage, with products being outsourced. Management views it as a potential long-term growth avenue, aligning with the broader Tata strategy in agriculture and the increasing demand for animal origin protein. The business has already scaled to over ₹50 crores, and the company plans to assess its strategy for another year before making significant investment decisions, indicating a cautious yet optimistic approach.

For advanced seed technologies like gene editing, Rallis's strategy is to license technologies rather than investing heavily in in-house R&D. This approach leverages the disproportionate R&D capabilities of global multinationals and avoids long development cycles. The company's cotton business is built on BT technology, and they are launching a Paryan technology-led rice seed business, which will feature a herbicide-tolerant gene and be sold as a bundled product.